Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis

Kenneth O'Byrne,Evan Popoff,Firas Badin,Adam Lee,Yong Yuan,Greta Lozano-Ortega,Laura J Eccles,Nebibe Varol,Nathalie Waser,John R Penrod, Sarah Goring

Lung Cancer（2023）

引用 3|浏览7

暂无评分

摘要

•Nivolumab + ipilimumab increases long-term OS relative to chemotherapy+/−IO in the first-line advanced NSCLC setting.•OS benefits were observed irrespective of histology or PD-L1 expression.•Treatments were compared using a statistical framework accommodating time-dependent hazard ratios.

查看译文

关键词

Advanced lung cancer,Network meta-analysis,Overall survival,Progression-free survival,Immunotherapies

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要